作　　者： ; ; ; ;

机构地区： 高州市人民医院

出　　处： 《临床医学工程》 2019年第12期1701-1702,共2页

摘　　要： 目的观察尼妥珠单抗联合同步放化疗治疗鼻咽癌的临床疗效。方法选择2016年4月至2019年4月我院收治的鼻咽癌患者86例,随机分为两组各43例。对照组行同步放化疗治疗,研究组在此基础上联合尼妥珠单抗治疗。比较两组的治疗效果、不良反应,以及TGF-β1、VEGF水平。结果研究组的治疗总有效率显著高于对照组(P<0.05)。治疗6周后,研究组的TGF-β1、VEGF水平显著低于对照组(P<0.05)。两组的不良反应发生率比较,差异无统计学意义(P>0.05)。结论尼妥珠单抗联合同步放化疗治疗鼻咽癌的疗效显著,可有效降低TGF-β1及VEGF水平,且不良反应可耐受。 Objective To observe the efficacy of nimotuzumab combined with concurrent chemoradiotherapy in the treatment of nasopharyngeal carcinoma. Methods 86 patients with nasopharyngeal carcinoma admitted to our hospital from April 2016 to April 2019 were selected and randomly divided into two groups, with 43 cases in each group. The control group was treated with concurrent chemoradiotherapy, and the study group was treated with nimotuzumab on the basis of control group. The therapeutic effect, adverse reactions, and levels of TGF-β1 and VEGF were compared between the two groups. Results The total effective rate of study group was significantly higher than that of control group(P<0.05). After 6 weeks of treatment, the levels of TGF-β1 and VEGF of study group were significantly lower than those of control group(P<0.05). No significant difference was found in the incidence of adverse reactions between two groups(P>0.05). Conclusions Nimotuzumab combined with concurrent chemoradiotherapy in the treatment of nasopharyngeal carcinoma has significant efficacy and tolerable adverse reactions, which can effectively reduce the levels of TGF-β1 and VEGF.

关 键 词： 鼻咽癌 尼妥珠单抗 同步放化疗 不良反应

领　　域： []